.png){kind=icon}
.png){kind=icon}
Return
Anticoagulation in critical care
.png){kind=icon}
PRE
AI
DOI：10.1007/s00063-026-01432-7.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Anticoagulation is used in intensive care medicine to prevent and treat thromboembolism. The increased risk of bleeding in this patient population requires a personalized approach to management including individualized anticoagulant selection and dose adjustment. While low-molecular-weight heparins are equivalent or superior to unfractionated heparin for thromboprophylaxis, unfractionated heparin is the preferred therapy for the treatment of thromboembolism. Its advantages include a relatively short half-life, the ability to monitor therapy using the activated partial thromboplastin time and the possibility of rapid and effective reversal. The direct thrombin inhibitor argatroban is a reserve anticoagulant used to treat patients with heparin-induced thrombocytopenia. The advantages of argatroban are its short half-life, hepatic clearance, and the ability to monitor therapeutic levels using the activated partial thromboplastin time.
Keywords:
Thrombosis
Prevention and control
Hemorrhage
Drug monitoring
Heparin
Thrombosis
Prevention and control
Hemorrhage
Drug monitoring
Heparin
Journal
M
IF:
1.5
Papers:
120
Citations:
0